Revvity二季度收入7.11亿美元、调整EPS 1.41美元并上调全年指引，但部分超预期来自一次性关税退款

BofA says this memory stock could double. Here are 5 reasons why
Introduction & Market Context
Revvity presented its second quarter 2026 earnings results on August 4, revealing a mixed performance that beat analyst expectations but prompted a premarket stock decline of 3.68% to $110.98. The scientific solutions company delivered pro forma revenue of $711 million and adjusted earnings per share of $1.41, with results bolstered by strong diagnostics growth and significant one-time tariff refunds that contributed approximately $0.11 to EPS.
The presentation highlighted a strategic inflection point for the company, with management emphasizing innovation in AI-driven laboratory solutions and improving market conditions in pharma and biotech end markets. However, investors appeared cautious about the sustainability of the beat given the material contribution from non-recurring items and continued weakness in the life sciences software business.
Quarterly Performance Highlights
As detailed in the company’s financial results summary, Revvity’s second quarter demonstrated solid operational execution across most metrics. Pro forma revenue increased 4% year-over-year, with organic growth of 3%, M&A contributions of 1%, and neutral foreign exchange impact.
The company’s adjusted operating margin reached 29.3%, representing a substantial 280 basis point improvement from the prior year period. This margin expansion was supported by an adjusted gross margin of 62.3%, up 200 basis points year-over-year. Management noted that pro forma adjusted operating income and EPS benefited by $16 million and approximately $0.11 respectively from tariff-related refunds, which accounted for roughly half of the earnings beat versus analyst expectations.
Free cash flow generation remained robust at $184 million for the quarter, with year-to-date free cash flow representing 108% of adjusted net income. This strong cash generation enabled the company to retire a €500 million note in July, further strengthening its balance sheet and positioning gross leverage to fall below 3x by year-end.
Segment Performance Analysis
The quarter revealed a clear divergence in performance between Revvity’s two main business segments. The company’s revenue composition and segment trends are illustrated in the following breakdown:
The diagnostics segment emerged as the clear growth driver, generating $352 million in revenue with reported growth of 12% and organic growth of 11%. The segment’s adjusted operating margin expanded dramatically to 30.4%, up 520 basis points year-over-year, driven by volume leverage, operational efficiency initiatives, and the benefit of tariff refunds.
Within diagnostics, immunodiagnostics showed high-single-digit growth with broad-based strength across the portfolio, while reproductive health delivered double-digit growth fueled by strength in newborn screening and partnership revenues. Management noted that the diagnostics adjusted operating margin included a 90 basis point headwind from the China immunodiagnostics business that the company has agreed to divest.
In contrast, the life sciences segment faced headwinds, with revenue of $359 million declining 2% on a reported basis and 3% organically. The segment’s adjusted operating margin of 31.1% represented a 50 basis point decline year-over-year.
The life sciences weakness was primarily concentrated in the software business, which declined approximately double-digits due to contract renewal timing and difficult year-over-year comparisons. However, life sciences solutions showed positive low-single-digit growth in both reagents and instruments. Management attributed the margin pressure to software volume declines and strategic investments in the business. Within the segment’s customer base, pharma and biotech customers showed mid-single-digit declines while academic and government customers declined in the low-single digits, both affected by the software performance.
Strategic Initiatives and Innovation
Revvity’s presentation emphasized three strategic pillars: innovation, market positioning, and operational performance. The company’s key takeaways from the quarter highlight its focus on emerging technologies and market expansion:
On the innovation front, Revvity launched several significant products during the quarter. The company introduced Signals AI, an artificial intelligence-powered enhancement to its laboratory informatics platform, along with a Signals Anthropic connector that integrates advanced language models into research workflows. The new Signals for Startups program aims to make the platform more accessible to smaller biotech companies, potentially expanding the company’s addressable market.
In diagnostics, Revvity achieved FDA clearance for its testosterone assay, adding to its menu of immunodiagnostics tests. This regulatory milestone supports the company’s strategy of expanding its diagnostic test offerings and strengthening its competitive position in clinical laboratories.
The company also made progress on portfolio optimization, signing a definitive agreement to divest its China immunodiagnostics business. This divestiture is expected to streamline operations and allow management to focus resources on higher-growth, higher-margin opportunities in other geographic markets. Throughout the presentation, management noted that diagnostics trends remained strong outside of China, validating the strategic rationale for the divestiture.
Forward-Looking Guidance and Outlook
Based on the second quarter performance and improved market visibility, Revvity raised its full-year 2026 financial guidance across multiple metrics. The updated outlook reflects management’s increased confidence in both near-term execution and the sustainability of recent market improvements.
The company now expects pro forma revenue of $2.83 billion to $2.86 billion, representing total growth of 5% to 6% and organic growth of 4% to 5%. This compares favorably to the company’s previous guidance and incorporates modest contributions from M&A activity (0.75%) and foreign exchange (0.5%). The adjusted operating margin target of 28.7% represents a 30 basis point increase from prior guidance, reflecting both operational improvements and the partial reinvestment of tariff refund benefits.
Adjusted EPS guidance was raised to a range of $5.30 to $5.40, up from the previous range of $5.20 to $5.30. This outlook assumes adjusted net interest expense and other items of approximately $90 million, an adjusted tax rate of around 18%, and an average diluted share count of approximately 112 million shares.
For the third quarter specifically, management guided to organic growth of 4% to 6%, revenue of $685 million to $700 million, and an adjusted operating margin of approximately 29%. The full-year outlook assumes continued strength in diagnostics, stabilization and gradual improvement in life sciences software, and increasing contribution from AI-related demand in instrumentation and reagents.
Risk Factors and Market Challenges
Despite the positive headline results and raised guidance, several challenges and uncertainties warrant investor attention. The quality of the second quarter earnings beat came under scrutiny given that approximately half of the EPS upside stemmed from one-time tariff refunds and favorable tax timing rather than purely operational outperformance. While management plans to reinvest a portion of these benefits into supply chain capacity and personnel, the non-recurring nature of the tariff refunds raises questions about the sustainability of margin expansion.
The ongoing weakness in life sciences software presents another concern. With the business declining approximately 20% organically in the quarter, management faces pressure to demonstrate that the second-half recovery in software revenue is achievable. While executives attributed the decline to contract renewal timing and difficult comparisons, the software business’s volatility creates uncertainty around the company’s ability to meet its full-year targets.
Geographic concentration risk remains relevant, particularly given the company’s decision to divest its China immunodiagnostics operation. This divestiture, while strategically sound, underscores the challenges of operating in that market and removes a revenue stream from the business. The company’s ability to offset this loss through growth in other regions will be critical to achieving its long-term objectives.
Finally, execution risk surrounds the company’s investments in AI-driven solutions and laboratory automation. While management expressed optimism about early signs of AI-related demand, Revvity is still in the early stages of capitalizing on this trend. The company must successfully convert its technology investments and product launches into sustained revenue growth while competing against well-established players in both the life sciences and diagnostics markets.
The stock’s premarket decline of 3.68% following the earnings release suggests investors remain cautious despite the raised guidance, focusing on the quality of the beat and the mixed performance across business segments rather than the headline numbers alone.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.